{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T04:55:14Z","timestamp":1649048114355},"reference-count":73,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2019,11,13]],"date-time":"2019-11-13T00:00:00Z","timestamp":1573603200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,11,13]],"date-time":"2019-11-13T00:00:00Z","timestamp":1573603200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hautarzt"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1007\/s00105-019-04496-z","type":"journal-article","created":{"date-parts":[[2019,11,13]],"date-time":"2019-11-13T13:22:12Z","timestamp":1573651332000},"page":"975-988","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Supportivtherapie und Nebenwirkungsmanagement in der Dermatoonkologie"],"prefix":"10.1007","volume":"70","author":[{"given":"Laura","family":"von D\u00fccker","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Svea","family":"H\u00fcning","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katharina","family":"K\u00e4hler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Terheyden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Do\ufeffro\ufeffth\u00e9e","family":"Nashan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,11,13]]},"reference":[{"key":"4496_CR1","volume-title":"Supportive Therapie bei onkologischen PatientInnen - Langversion 1.1, AWMF Registernummer: 032\/054OL","author":"Deutsche Krebsgesellschaft","year":"2017","unstructured":"Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF (2017) Supportive Therapie bei onkologischen PatientInnen - Langversion 1.1, AWMF Registernummer: 032\/054OL. https:\/\/www.awmf.org\/uploads\/tx_szleitlinien\/032-054OLl_S3_Supportiv_2017-05.pdf. Zugegriffen: 8. Juli 2019"},{"key":"4496_CR2","volume-title":"About MASCC","author":"MASCC","year":"2019","unstructured":"MASCC (2019) About MASCC. https:\/\/www.mascc.org\/about-mascc. Zugegriffen: 8. Juli 2019"},{"issue":"6","key":"4496_CR3","first-page":"278","volume":"16","author":"L Radbruch","year":"2009","unstructured":"Radbruch\u00a0L, Payne\u00a0S et\u00a0al (2009) White Paper on standards and norms for hospice and palliative care in Europe: part 1. Eur J Palliat Care 16(6):278\u2013289","journal-title":"Eur J Palliat Care"},{"issue":"2","key":"4496_CR4","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s00520-007-0354-4","volume":"16","author":"JF Smyth","year":"2008","unstructured":"Smyth\u00a0JF (2008) Disclosing gaps between supportive and palliative care: the past 20 years. Support Care Cancer 16(2):109\u2013111","journal-title":"Support Care Cancer"},{"key":"4496_CR5","volume-title":"Palliativmedizin f\u00fcr Patienten mit einer nicht heilbaren Krebserkrankung, Langversion 1.1, AWMF-Registernummer: 128\/001OL","author":"Deutsche Krebsgesellschaft","year":"2015","unstructured":"Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF (2015) Palliativmedizin f\u00fcr Patienten mit einer nicht heilbaren Krebserkrankung, Langversion 1.1, AWMF-Registernummer: 128\/001OL. https:\/\/www.dgpalliativmedizin.de\/images\/stories\/LL_Palliativmedizin_Langversion_1_1.pdf. Zugegriffen: 8. Juli 2019"},{"key":"4496_CR6","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","volume":"373","author":"J Larkin","year":"2015","unstructured":"Larkin\u00a0J, Chiarion-Sileni\u00a0V, Gonzalez\u00a0R et al (2015) Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N\u00a0Engl J Med 373:23\u201334","journal-title":"N Engl J Med"},{"issue":"11","key":"4496_CR7","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1016\/S1470-2045(18)30700-9","volume":"19","author":"FS Hodi","year":"2018","unstructured":"Hodi\u00a0FS, Chiarion-Sileni\u00a0V, Gonzalez\u00a0R et al (2018) Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4\u2011year outcomes of a\u00a0multicentre, randomised, phase 3 trial. Lancet Oncol 19(11):1480\u20131492","journal-title":"Lancet Oncol"},{"issue":"29\u201330","key":"4496_CR8","first-page":"497","volume":"116","author":"P Terheyden","year":"2019","unstructured":"Terheyden\u00a0P, Krackhardt\u00a0A, Eigentler\u00a0T (2019) Systemtherapie des Melanoms. Einsatz von Immuncheckpoint-Inhibitoren und Hemmung von intrazellul\u00e4rer Signaltransduktion. Dtsch Arztebl Int 116(29\u201330):497\u2013504","journal-title":"Dtsch Arztebl Int"},{"issue":"4","key":"4496_CR9","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1056\/NEJMoa1805131","volume":"379","author":"MR Migden","year":"2018","unstructured":"Migden\u00a0MR, Rischin\u00a0D, Schmults\u00a0CD et al (2018) PD\u20111 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma. N\u00a0Engl J Med 379(4):341\u2013351","journal-title":"N Engl J Med"},{"issue":"2","key":"4496_CR10","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s13555-019-0288-z","volume":"9","author":"A Villani","year":"2019","unstructured":"Villani\u00a0A, Fabbrocini\u00a0G, Costa\u00a0C et\u00a0al (2019) Merkel cell carcinoma: therapeutic update and emerging therapies. Dermatol Ther (Heidelb) 9(2):209\u2013222","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"Suppl 4","key":"4496_CR11","doi-asserted-by":"crossref","first-page":"iv264","DOI":"10.1093\/annonc\/mdy162","volume":"29","author":"JBAG Haanen","year":"2018","unstructured":"Haanen\u00a0JBAG, Carbonnel\u00a0F, Robert\u00a0C et al (2018) Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 29(Suppl 4):iv264\u2013iv266","journal-title":"Ann Oncol"},{"issue":"3","key":"4496_CR12","doi-asserted-by":"crossref","first-page":"e000491","DOI":"10.1136\/esmoopen-2019-000491","volume":"4","author":"L Heinzerling","year":"2019","unstructured":"Heinzerling\u00a0L, Eigentler\u00a0TK, Fluck\u00a0M et\u00a0al (2019) Tolerability of BRAF\/MEK inhibitor combinations: adverse event evaluation and management. ESMO Open 4(3):e491","journal-title":"ESMO Open"},{"issue":"7","key":"4496_CR13","first-page":"662","volume":"14","author":"KC K\u00e4hler","year":"2016","unstructured":"K\u00e4hler\u00a0KC, Hassel\u00a0JC, Heinzerling\u00a0L et al (2016) Management of side effects of immune checkpoint blockade by anti-CTLA\u20114 and anti-PD\u20111 antibodies in metastatic melanoma. J\u00a0Dtsch Dermatol Ges 14(7):662\u2013681","journal-title":"J Dtsch Dermatol Ges"},{"issue":"17","key":"4496_CR14","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","volume":"36","author":"JR Brahmer","year":"2018","unstructured":"Brahmer\u00a0JR, Lacchetti\u00a0C, Schneider\u00a0BJ et al (2018) Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline. J\u00a0Clin Oncol 36(17):1714\u20131768","journal-title":"J Clin Oncol"},{"issue":"1","key":"4496_CR15","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","volume":"5","author":"I Puzanov","year":"2017","unstructured":"Puzanov\u00a0I, Diab\u00a0A, Abdallah\u00a0K et\u00a0al (2017) Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J\u00a0Immunother Cancer 5(1):95. https:\/\/doi.org\/10.1186\/s40425-017-0300-z","journal-title":"J Immunother Cancer"},{"issue":"9","key":"4496_CR16","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/S1470-2045(16)30122-X","volume":"17","author":"PA Ascierto","year":"2016","unstructured":"Ascierto\u00a0PA, McArthur\u00a0GA, Dr\u00e9no\u00a0B et al (2016) Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a\u00a0randomised, double-blind, phase 3 trial. Lancet Oncol 17(9):1248\u20131260","journal-title":"Lancet Oncol"},{"issue":"5","key":"4496_CR17","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S1470-2045(18)30142-6","volume":"19","author":"R Dummer","year":"2018","unstructured":"Dummer\u00a0R, Ascierto\u00a0PA, Gogas\u00a0HJ et al (2018) Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a\u00a0multicentre, open-label, randomised phase 3 trial. Lancet Oncol 19(5):603\u2013615","journal-title":"Lancet Oncol"},{"issue":"3","key":"4496_CR18","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s11523-018-0571-4","volume":"13","author":"M Shirley","year":"2018","unstructured":"Shirley\u00a0M (2018) Avelumab: a review in metastatic Merkel cell carcinoma. Target Oncol 13(3):409\u2013416","journal-title":"Target Oncol"},{"issue":"10","key":"4496_CR19","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.1007\/s00520-017-3802-9","volume":"25","author":"BL Rapoport","year":"2017","unstructured":"Rapoport\u00a0BL, van Eeden\u00a0R, Sibaud\u00a0V et\u00a0al (2017) Supportive care for patients undergoing immunotherapy. Support Care Cancer 25(10):3017\u20133030","journal-title":"Support Care Cancer"},{"key":"4496_CR20","doi-asserted-by":"crossref","first-page":"53","DOI":"10.4137\/CMO.S5855","volume":"6","author":"C Lemech","year":"2012","unstructured":"Lemech\u00a0C, Arkenau\u00a0HT (2012) Novel treatments for metastatic cutaneous melanoma and the management of emergent toxicities. Clin Med Insights Oncol 6:53\u201366","journal-title":"Clin Med Insights Oncol"},{"key":"4496_CR21","volume-title":"Ern\u00e4hrung bei Krebs","author":"Deutsche Krebshilfe","year":"2017","unstructured":"Deutsche Krebshilfe (2017) Ern\u00e4hrung bei Krebs. https:\/\/www.krebshilfe.de\/infomaterial\/Blaue_Ratgeber\/Ernaehrung-bei-Krebs_BlaueRatgeber_DeutscheKrebshilfe.pdf. Zugegriffen: 8. Juli 2019"},{"issue":"7","key":"4496_CR22","doi-asserted-by":"crossref","first-page":"915","DOI":"10.6004\/jnccn.2016.0094","volume":"14","author":"MP Davis","year":"2016","unstructured":"Davis\u00a0MP (2016) Cannabinoids for symptom management and cancer therapy: the evidence. J\u00a0Natl Compr Canc Netw 14(7):915\u2013922","journal-title":"J Natl Compr Canc Netw"},{"issue":"1","key":"4496_CR23","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1097\/PPO.0000000000000296","volume":"24","author":"DY Wang","year":"2018","unstructured":"Wang\u00a0DY, Johnson\u00a0DB, Davis\u00a0EJ (2018) Toxicities associated with PD-1\/PD-L1 blockade. Cancer\u00a0J 24(1):36\u201340","journal-title":"Cancer J"},{"issue":"4","key":"4496_CR24","first-page":"422","volume":"9","author":"JE Bala-Hampton","year":"2018","unstructured":"Bala-Hampton\u00a0JE, Bazzell\u00a0AF, Dains\u00a0JE (2018) Clinical management of pneumonitis in patients receiving anti-PD-1\/PD-L1 therapy. J\u00a0Adv Pract Oncol 9(4):422\u2013428","journal-title":"J Adv Pract Oncol"},{"issue":"28","key":"4496_CR25","doi-asserted-by":"crossref","first-page":"3240","DOI":"10.1200\/JCO.2017.74.4789","volume":"35","author":"PJ Hesketh","year":"2015","unstructured":"Hesketh\u00a0PJ, Kris\u00a0MG, Basch\u00a0E et\u00a0al (2015) Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J\u00a0Clin Oncol 35(28):3240\u20133261","journal-title":"J Clin Oncol"},{"key":"4496_CR26","first-page":"CD010106","volume":"9","author":"JS Furyk","year":"2015","unstructured":"Furyk\u00a0JS, Meek\u00a0RA, Egerton-Warburton\u00a0D (2015) Drugs for the treatment of nausea and vomiting in adults in the emergency department setting. Cochrane Database Syst Rev 9:CD10106","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"4496_CR27","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1634\/theoncologist.2014-0229","volume":"20","author":"M Aapro","year":"2015","unstructured":"Aapro\u00a0M, Carides\u00a0A, Rapoport\u00a0BL (2015) Aprepitant and fosaprepitant: a\u00a010-year review of efficacy and safety. Oncologist 20(4):450\u2013458","journal-title":"Oncologist"},{"issue":"3","key":"4496_CR28","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.jhep.2016.11.015","volume":"66","author":"M Ziemer","year":"2017","unstructured":"Ziemer\u00a0M, Koukoulioti\u00a0E, Beyer\u00a0S et al (2017) Managing immune checkpoint-inhibitor-induced severe autoimmune-like hepatitis by liver-directed topical steroids. J\u00a0Hepatol 66(3):657\u2013659","journal-title":"J Hepatol"},{"issue":"8","key":"4496_CR29","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1016\/j.dld.2019.06.017","volume":"51","author":"A Lleo","year":"2019","unstructured":"Lleo\u00a0A, Rimassa\u00a0L, Colombo\u00a0M (2019) Hepatotoxicity of immune check point inhibitors: Approach and management. Dig Liver Dis 51(8):1074\u20131078. https:\/\/doi.org\/10.1016\/j.dld.2019.06.017","journal-title":"Dig Liver Dis"},{"issue":"6","key":"4496_CR30","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1007\/s10620-014-3473-z","volume":"60","author":"AJ Montano-Loza","year":"2015","unstructured":"Montano-Loza\u00a0AJ, Czaja\u00a0AJ (2015) Cell mediators of autoimmune hepatitis and their therapeutic implications. Dig Dis Sci 60(6):1528\u20131542","journal-title":"Dig Dis Sci"},{"issue":"2","key":"4496_CR31","doi-asserted-by":"crossref","first-page":"177","DOI":"10.5009\/gnl15352","volume":"10","author":"AJ Czaja","year":"2016","unstructured":"Czaja\u00a0AJ (2016) Diagnosis and management of autoimmune hepatitis: current status and future directions. Gut Liver 10(2):177\u2013203","journal-title":"Gut Liver"},{"issue":"4","key":"4496_CR32","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1111\/jgh.12888","volume":"30","author":"R Cheng","year":"2015","unstructured":"Cheng\u00a0R, Cooper\u00a0A, Kench\u00a0J et al (2015) Ipilimumab-induced toxicities and the gastroenterologist. J\u00a0Gastroenterol Hepatol 30(4):657\u2013666","journal-title":"J Gastroenterol Hepatol"},{"issue":"4","key":"4496_CR33","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s00262-017-2107-7","volume":"67","author":"HM McGuire","year":"2018","unstructured":"McGuire\u00a0HM, Shklovskaya\u00a0E, Edwards\u00a0J et al (2018) Anti-PD-1-induced high-grade hepatitis associated with corticosteroid-resistant T cells: a\u00a0case report. Cancer Immunol Immunother 67(4):563\u2013573","journal-title":"Cancer Immunol Immunother"},{"key":"4496_CR34","doi-asserted-by":"crossref","first-page":"5361569","DOI":"10.1155\/2016\/5361569","volume":"2016","author":"B Gen\u00e7ler","year":"2016","unstructured":"Gen\u00e7ler\u00a0B, G\u00f6n\u00fcl\u00a0M (2016) Cutaneous side effects of BRAF inhibitors in advanced melanoma: review of the literature. Dermatol Res Pract 2016:5361569","journal-title":"Dermatol Res Pract"},{"issue":"7","key":"4496_CR35","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1634\/theoncologist.2016-0456","volume":"22","author":"A Daud","year":"2017","unstructured":"Daud\u00a0A, Tsai\u00a0K (2017) Management of treatment-related adverse events with agents targeting the MAPK pathway in patients with metastatic melanoma. Oncologist 22(7):823\u2013833","journal-title":"Oncologist"},{"issue":"3","key":"4496_CR36","first-page":"29","volume":"3","author":"E Livingstone","year":"2014","unstructured":"Livingstone\u00a0E, Zimmer\u00a0L, Vaubel\u00a0J et\u00a0al (2014) BRAF, MEK and KIT inhibitors for melanoma: adverse events and their management. Chin Clin Oncol 3(3):29","journal-title":"Chin Clin Oncol"},{"key":"4496_CR37","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/5036213","author":"I Russo","year":"2018","unstructured":"Russo\u00a0I, Zorzetto\u00a0L, Chiarion Sileni\u00a0V et\u00a0al (2018) Cutaneous side effects of targeted therapy and immunotherapy for advanced melanoma. Scientifica (Cairo). https:\/\/doi.org\/10.1155\/2018\/5036213","journal-title":"Scientifica (Cairo)"},{"issue":"8","key":"4496_CR38","first-page":"119","volume":"116","author":"L Heinzerling","year":"2019","unstructured":"Heinzerling\u00a0L, de Toni\u00a0E, Schett\u00a0G et al (2019) Checkpoint-Inhibitoren. Diagnostik und Therapie von Nebenwirkungen. Dtsch Arztebl Int 116(8):119\u2013126","journal-title":"Dtsch Arztebl Int"},{"key":"4496_CR39","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.ejca.2018.06.030","volume":"101","author":"G Ben-Betzalel","year":"2018","unstructured":"Ben-Betzalel\u00a0G, Baruch\u00a0EN, Boursi\u00a0B et al (2018) Possible immune adverse events as predictors of durable response to BRAF inhibitors in patients with BRAF V600-mutant metastatic melanoma. Eur J Cancer 101:229\u2013235","journal-title":"Eur J Cancer"},{"issue":"1","key":"4496_CR40","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1001\/jamadermatol.2015.2707","volume":"152","author":"C Hua","year":"2016","unstructured":"Hua\u00a0C, Boussemart\u00a0L, Mateus\u00a0C (2016) Association of vitiligo with tumor response in patients with metastatic melanoma treated with pembrolizumab. JAMA Dermatol 152(1):45\u201351","journal-title":"JAMA Dermatol"},{"key":"4496_CR41","volume-title":"S2k-Leitlinie zur Diagnostik und Therapie des chronischen Pruritus","author":"S St\u00e4nder","year":"2016","unstructured":"St\u00e4nder\u00a0S, Zeidler\u00a0C, Augustin\u00a0M, Bayer\u00a0G, Kremer\u00a0AE, Legat\u00a0FJ, Maisel\u00a0P, Mettang\u00a0T, Metz\u00a0M, Nast\u00a0A, Niemeier\u00a0V, Raap\u00a0U, Schneider\u00a0G, St\u00e4nder\u00a0H, Staubach\u00a0P, Streit\u00a0M, Weisshaar\u00a0E (2016) S2k-Leitlinie zur Diagnostik und Therapie des chronischen Pruritus. https:\/\/www.awmf.org\/uploads\/tx_szleitlinien\/013-048l_S2k_Chronischer_Pruritus_2017-01.pdf. Zugegriffen: 11. Juli 2019"},{"issue":"3","key":"4496_CR42","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s12012-012-9164-0","volume":"12","author":"M Svoboda","year":"2012","unstructured":"Svoboda\u00a0M, Poprach\u00a0A, Dobes\u00a0S et\u00a0al (2012) Cardiac toxicity of targeted therapies used in the treatment for solid tumours: a\u00a0review. Cardiovasc Toxicol 12(3):191\u2013207","journal-title":"Cardiovasc Toxicol"},{"key":"4496_CR43","first-page":"28","volume":"99","author":"W Haverkamp","year":"2002","unstructured":"Haverkamp\u00a0W, Haverkamp\u00a0F, Breithardt\u00a0G (2002) Medikamentenbedingte QT-Verl\u00e4ngerung und Torsade de pointes: Ein multidisziplin\u00e4res Problem. Dtsch Arztebl 99:28\u201329","journal-title":"Dtsch Arztebl"},{"issue":"7","key":"4496_CR44","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1007\/s11936-019-0731-6","volume":"21","author":"L Zhang","year":"2019","unstructured":"Zhang\u00a0L, Jones-O\u2019Connor\u00a0M, Awadalla\u00a0M et al (2019) Cardiotoxicity of immune checkpoint inhibitors. Curr Treat Options Cardiovasc Med 21(7):32","journal-title":"Curr Treat Options Cardiovasc Med"},{"key":"4496_CR45","volume-title":"2016 guidelines for the diagnosis and treatment of acute and chronic heart failure","author":"The Task Force for the Diagnosis and Treatment Acute and Chronic Heart Failure 2016 of the European Society of Cardiology","year":"2017","unstructured":"The Task Force for the Diagnosis and Treatment Acute and Chronic Heart Failure 2016 of the European Society of Cardiology (2017) 2016 guidelines for the diagnosis and treatment of acute and chronic heart failure. https:\/\/leitlinien.dgk.org\/files\/PLL_2017_HI_Auflage2.pdf. Zugegriffen: 8. Juli 2019"},{"key":"4496_CR46","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s40425-015-0057-1","volume":"3","author":"H L\u00e4ubli","year":"2015","unstructured":"L\u00e4ubli\u00a0H, Balmelli\u00a0C, Bossard\u00a0M et\u00a0al (2015) Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma. J\u00a0Immunother Cancer 3:11","journal-title":"J Immunother Cancer"},{"issue":"11","key":"4496_CR47","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.2174\/0929867324666170407125017","volume":"25","author":"G Varricchi","year":"2018","unstructured":"Varricchi\u00a0G, Marone\u00a0G, Mercurio\u00a0V et\u00a0al (2018) Immune checkpoint inhibitors and cardiac toxicity: an emerging issue. Curr Med Chem 25(11):1327\u20131339","journal-title":"Curr Med Chem"},{"issue":"4","key":"4496_CR48","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s12012-017-9425-z","volume":"17","author":"M Banks","year":"2017","unstructured":"Banks\u00a0M, Crowell\u00a0K, Proctor\u00a0A et\u00a0al (2017) Cardiovascular effects of the MEK inhibitor, trametinib: a case report, literature review, and consideration of mechanism. Cardiovasc Toxicol 17(4):487\u2013493","journal-title":"Cardiovasc Toxicol"},{"key":"4496_CR49","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1007\/s40618-018-0984-z","volume":"42","author":"RM Ruggeri","year":"2019","unstructured":"Ruggeri\u00a0RM, Campenni\u00a0A, Giuffrida\u00a0G et\u00a0al (2019) Endocrine and metabolic adverse effects of immune checkpoint inhibitors: an overview (what endocrinologists should know). J\u00a0Endocrinol Invest 42:745\u2013756","journal-title":"J Endocrinol Invest"},{"issue":"1","key":"4496_CR50","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/s11102-015-0671-4","volume":"19","author":"A Faje","year":"2016","unstructured":"Faje\u00a0A (2016) Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights. Pituitary 19(1):82\u201392","journal-title":"Pituitary"},{"key":"4496_CR51","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1530\/EJE-14-0845","volume":"172","author":"F Albarel","year":"2015","unstructured":"Albarel\u00a0F, Gaudy\u00a0C, Castinetti\u00a0F et al (2015) Long-term follow-up of ipilimumab-induced hypophysitis, a\u00a0common adverse event of the anti-CTLA\u20114 antibody in melanoma. Eur J Endocrinol 172:195\u2013204","journal-title":"Eur J Endocrinol"},{"key":"4496_CR52","doi-asserted-by":"publisher","DOI":"10.1177\/2042018818821294","author":"A Oprea","year":"2019","unstructured":"Oprea\u00a0A, Bonnet\u00a0NC, Poll\u00e9\u00a0O, Lysy\u00a0PA (2019) Novel insights into glucocorticoid replacement therapy for pediatric and adult adrenal insufficiency. Ther Adv Endocrinol Metab. https:\/\/doi.org\/10.1177\/2042018818821294","journal-title":"Ther Adv Endocrinol Metab"},{"issue":"51\u201352","key":"4496_CR53","first-page":"882","volume":"110","author":"M Quinkler","year":"2013","unstructured":"Quinkler\u00a0M, Beuschlein\u00a0F, Hahner\u00a0S et al (2013) Nebennierenrinden-Insuffizienz \u2013 lebensbedrohliche Erkrankung mit vielf\u00e4ltigen Ursachen. Dtsch Arztebl Int 110(51\u201352):882\u2013888","journal-title":"Dtsch Arztebl Int"},{"key":"4496_CR54","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-019-04883-1","author":"Y Wang","year":"2019","unstructured":"Wang\u00a0Y, Logan\u00a0S, Stern\u00a0K et\u00a0al (2019) Supportive oncofertility care, psychological health and reproductive concerns: a qualitative study. Support Care Cancer. https:\/\/doi.org\/10.1007\/s00520-019-04883-1","journal-title":"Support Care Cancer"},{"issue":"5","key":"4496_CR55","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s00120-018-0635-1","volume":"57","author":"MO Grimm","year":"2018","unstructured":"Grimm\u00a0MO, Oppel-Heuchel\u00a0H, Foller\u00a0S (2018) Therapie mit PD-1\/PD-L1- und CTLA-4-Immun-Checkpoint-Inhibitoren. Urologe\u00a0A 57(5):543\u2013551","journal-title":"Urologe A"},{"issue":"10","key":"4496_CR56","first-page":"739","volume":"31","author":"A Balaji","year":"2017","unstructured":"Balaji\u00a0A, Verde\u00a0F, Suresh\u00a0K, Naidoo\u00a0J (2017) Pneumonitis from anti-PD-1\/PD-L1 therapy. Oncology (Williston Park) 31(10):739\u2013746 (754)","journal-title":"Oncology (Williston Park)"},{"issue":"2","key":"4496_CR57","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1177\/1049909114552692","volume":"33","author":"MJ Johnson","year":"2016","unstructured":"Johnson\u00a0MJ, Hui\u00a0D, Currow\u00a0DC (2016) Opioids, exertion, and dyspnea: a review of the evidence. Am J Hosp Palliat Care 33(2):194\u2013200","journal-title":"Am J Hosp Palliat Care"},{"key":"4496_CR58","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ejca.2018.09.033","volume":"106","author":"A Moreira","year":"2019","unstructured":"Moreira\u00a0A, Loquai\u00a0C, Pf\u00f6hler\u00a0C et al (2019) Myositis and neuromuscular side-effects induced by immune checkpoint inhibitors. Eur J Cancer 106:12\u201323","journal-title":"Eur J Cancer"},{"issue":"14","key":"4496_CR59","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1212\/WNL.0000000000007235","volume":"92","author":"A Johansen","year":"2019","unstructured":"Johansen\u00a0A, Christensen\u00a0SJ, Scheie\u00a0D et al (2019) Neuromuscular adverse events associated with anti-PD\u20111 monoclonal antibodies: systematic review. Neurology 92(14):663\u2013674","journal-title":"Neurology"},{"issue":"1","key":"4496_CR60","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1024\/1012-5302.12.1.11","volume":"12","author":"A Glaus","year":"1999","unstructured":"Glaus\u00a0A, Crow\u00a0R, Hammond\u00a0S (1999) Fatigue in healthy and cancer patients II. A qualitative study on conceptual analysis. Pflege 12(1):11\u201319","journal-title":"Pflege"},{"issue":"3 Suppl 2","key":"4496_CR61","first-page":"4","volume":"34","author":"NJ Vogelzang","year":"1997","unstructured":"Vogelzang\u00a0NJ, Breitbart\u00a0W, Cella\u00a0D et al (1997) Patient, caregiver, and oncologist perceptions of cancer-related fatigue: results of a\u00a0tripart assessment survey. The Fatigue Coalition. Semin Hematol 34(3 Suppl 2):4\u201312","journal-title":"Semin Hematol"},{"issue":"25","key":"4496_CR62","doi-asserted-by":"crossref","first-page":"3076","DOI":"10.1200\/JCO.2012.44.4661","volume":"31","author":"S Yennurajalingam","year":"2013","unstructured":"Yennurajalingam\u00a0S, Frisbee-Hume\u00a0S, Palmer\u00a0JL et al (2013) Reduction of cancer-related fatigue with dexamethasone: a\u00a0double-blind, randomized, placebo-controlled trial in patients with advanced cancer. J\u00a0Clin Oncol 31(25):3076\u20133082","journal-title":"J Clin Oncol"},{"key":"4496_CR63","doi-asserted-by":"crossref","first-page":"4439","DOI":"10.1200\/JCO.2003.06.156","volume":"21","author":"E Bruera","year":"2003","unstructured":"Bruera\u00a0E, Driver\u00a0L, Barnes\u00a0EA et al (2003) Patient-controlled methylphenidate for the management of fatigue in patients with advanced cancer: a\u00a0preliminary report. J\u00a0Clin Oncol 21:4439\u20134443","journal-title":"J Clin Oncol"},{"issue":"16","key":"4496_CR64","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1093\/jnci\/djn250","volume":"100","author":"O Minton","year":"2008","unstructured":"Minton\u00a0O, Richardson\u00a0A, Sharpe\u00a0M et al (2008) A systematic review and meta-analysis of the pharmacological treatment of cancer-related fatigue. J\u00a0Natl Cancer Inst 100(16):1155\u20131166","journal-title":"J Natl Cancer Inst"},{"issue":"6","key":"4496_CR65","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1089\/acm.2010.0571","volume":"17","author":"MP De Oliveira Campos","year":"2011","unstructured":"De Oliveira Campos\u00a0MP, Riechelmann\u00a0R, Martins\u00a0LC et\u00a0al (2011) Guarana (Paullinia cupana) improves fatigue in breast cancer patients undergoing systemic chemotherapy. J\u00a0Altern Complement Med 17(6):505\u2013512","journal-title":"J Altern Complement Med"},{"issue":"5","key":"4496_CR66","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1177\/1534735415580676","volume":"14","author":"S Yennurajalingam","year":"2015","unstructured":"Yennurajalingam\u00a0S, Reddy\u00a0A, Tannir\u00a0NM et al (2015) High-dose Asian ginseng (Panax ginseng) for cancer-related fatigue: a preliminary report. Integr Cancer Ther 14(5):419\u2013427","journal-title":"Integr Cancer Ther"},{"issue":"1","key":"4496_CR67","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1093\/epirev\/mxx007","volume":"39","author":"P Cormie","year":"2017","unstructured":"Cormie\u00a0P, Zopf\u00a0EM, Zhang\u00a0X, Schmitz\u00a0KH (2017) The impact of exercise on cancer mortality, recurrence, and treatment-related adverse effects. Epidemiol Rev 39(1):71\u201392","journal-title":"Epidemiol Rev"},{"issue":"7","key":"4496_CR68","first-page":"353","volume":"21","author":"CM Dieli-Conwright","year":"2015","unstructured":"Dieli-Conwright\u00a0CM, Orozco\u00a0BZ (2015) Exercise after breast cancer treatment: current perspectives. Breast Cancer 21(7):353\u2013362","journal-title":"Breast Cancer"},{"issue":"8","key":"4496_CR69","first-page":"791","volume":"15","author":"B Buchhold","year":"2017","unstructured":"Buchhold\u00a0B, Arnold\u00a0A, Lutze\u00a0S et\u00a0al (2017) Psychosocial distress and desire for support among patients with skin cancer. J\u00a0Dtsch Dermatol Ges 15(8):791\u2013799","journal-title":"J Dtsch Dermatol Ges"},{"key":"4496_CR70","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/1477-7525-7-102","volume":"7","author":"A Montazeri","year":"2009","unstructured":"Montazeri\u00a0A (2009) Quality of life data as prognostic indicators of survival in cancer patients: an overview of the literature from 1982 to 2008. Health Qual Life Outcomes 7:102","journal-title":"Health Qual Life Outcomes"},{"key":"4496_CR71","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1007\/s00105-009-1814-1","volume":"60","author":"ME Beutel","year":"2009","unstructured":"Beutel\u00a0ME, Blettner\u00a0M, Fischbeck\u00a0S et\u00a0al (2009) Psychoonkologische Aspekte des malignen Melanoms. Hautarzt 60:727\u2013734","journal-title":"Hautarzt"},{"issue":"5","key":"4496_CR72","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1111\/ddg.13521_g","volume":"16","author":"F Meiss","year":"2018","unstructured":"Meiss\u00a0F, Loquai\u00a0C, Weis\u00a0J et\u00a0al (2018) Psychoonkologische Versorgung von Melanompatienten in zertifizierten Hautkrebszentren. J\u00a0Dtsch Dermatol Ges 16(5):577\u2013584","journal-title":"J Dtsch Dermatol Ges"},{"key":"4496_CR73","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1007\/s00105-013-2681-3","volume":"64","author":"A Albrecht","year":"2013","unstructured":"Albrecht\u00a0A, Meiss\u00a0F, Zeiss\u00a0T et\u00a0al (2013) Psychoonkologische Versorgung f\u00fcr Melanompatienten: Konzeption und Implementierung. Hautarzt 64:927\u2013930","journal-title":"Hautarzt"}],"container-title":["Der Hautarzt"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-019-04496-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00105-019-04496-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-019-04496-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,12]],"date-time":"2020-11-12T01:02:39Z","timestamp":1605142959000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00105-019-04496-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,13]]},"references-count":73,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["4496"],"URL":"https:\/\/doi.org\/10.1007\/s00105-019-04496-z","relation":{},"ISSN":["0017-8470","1432-1173"],"issn-type":[{"value":"0017-8470","type":"print"},{"value":"1432-1173","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,13]]},"assertion":[{"value":"13 November 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"Gem\u00e4\u00df den Richtlinien des Springer Medizin Verlags werden Autoren und Wissenschaftliche Leitung im Rahmen der Manuskripterstellung und Manuskriptfreigabe aufgefordert, eine vollst\u00e4ndige Erkl\u00e4rung zu ihren finanziellen und nichtfinanziellen Interessen abzugeben.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"<b>L. von D\u00fccker<\/b>: A. Finanzielle Interessen: L. von D\u00fccker gibt an, dass kein finanzieller Interessenkonflikt besteht. \u2013 B. Nichtfinanzielle Interessen: Assistenz\u00e4rztin in der Dermatologie, UKSH, Campus L\u00fcbeck | Mitgliedschaften: ADO, DDG. <b>S.\u00a0H\u00fcning<\/b>: A. Finanzielle Interessen: AbbVie: Vortrag \u201eImpfen und Biologica\u201c, Nurse Academy, Dortmund 11\/2016 | Ansonsten keine Honorare zu assoziierten Themen, Kongressen, Expertengremien. \u2013 B. Nichtfinanzielle Interessen: Assistenz\u00e4rztin, Klinikum Dortmund gGmbH, Neurhausstra\u00dfe\u00a040, 44137 Dortmund | Mitgliedschaften: ADO, ADH, DDG. <b>K.\u00a0K\u00e4hler<\/b>: A. Finanzielle Interessen: Forschungsf\u00f6rderung zur pers\u00f6nlichen Verf\u00fcgung: BMS, MSD, Novartis (jeweils Studienf\u00f6rderung). \u2013 Vortragshonorare und Reisekosten: MSD, BMS, Roche, Novartis, Philogen, Pierre Fabre. \u2013 Bezahlter Berater\/interner Schulungsreferent\/Gehaltsempf\u00e4nger o.\u202f\u00c4.: BMS, MSD. \u2013 B. Nichtfinanzielle Interessen: Ober\u00e4rztin am Universit\u00e4tsklinikum Schleswig-Holstein, Klinik f\u00fcr Dermatologie, Venerologie und Allergologie, Univ.-Hautklinik, Kiel. <b>P.\u00a0Terheyden<\/b>: A. Finanzielle Interessen: Vortragshonorar: BMS, Novartis, MSD, Pierre-Fabre, CureVac und Roche. Reise- oder \u00dcbernachtungskosten: BMS, Pierre-Fabre und Roche. \u2013 Beraterhonorare: BMS, Novartis, Pierre-Fabre, Merck Serono, Sanofi und Roche. \u2013 B. Nichtfinanzielle Interessen: Angestellter Arzt Klinik f\u00fcr Dermatologie, UK SH Campus L\u00fcbeck; Stv. Klinikdirektor | Mitgliedschaften: Deutsche Krebsgesellschaft; DDG. <b>D.\u00a0Nashan<\/b>: A. Finanzielle Interessen: D. Nashan gibt an, dass kein finanzieller Interessenkonflikt besteht. \u2013 B. Nichtfinanzielle Interessen: Chef\u00e4rztin\/Klinikdirektorin.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Autoren"}},{"value":"Die vollst\u00e4ndige Erkl\u00e4rung zum Interessenkonflikt der Wissenschaftlichen Leitung finden Sie am Kurs der zertifizierten Fortbildung auf ExternalRef removed.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Wissenschaftliche Leitung"}},{"value":"erkl\u00e4rt, dass f\u00fcr die Publikation dieser CME-Fortbildung keine Sponsorengelder an den Verlag flie\u00dfen.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}}]}}